Novavax Inc. (NVAX)
Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?
Retail traders are treating Novavax as a cancer-vaccine play today, but the price action shows a single-name bid rather than a sector move. Novavax (NASDAQ:NVAX) stock is up 6% to $9.90 in midday trading.
Novavax Stock Pulls Back After Milestone Vaccine Success
Drug stock Novavax Inc (NASDAQ:NVAX) is trading 2.8% lower at $9.18 this afternoon, pulling back from yesterday's surge to six-week highs.
NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised
Novavax beat Q2 earnings and revenue estimates, raises its 2026 adjusted revenue outlook, cuts expense guidance and outlines potential Sanofi milestones ahead.
Novavax Q2 Earnings Call Highlights
Novavax NASDAQ: NVAX reported second-quarter 2026 revenue of $57 million and a net loss of $53 million, while highlighting progress in its Sanofi partnership, expanding use of its Matrix-M adjuvant platform and continued cost reductions.
Novavax, Inc. (NVAX) Q2 2026 Earnings Call Transcript
Novavax, Inc. (NVAX) Q2 2026 Earnings Call Transcript
Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates
Novavax (NVAX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to earnings of $0.62 per share a year ago.
Are Medical Stocks Lagging Novavax (NVAX) This Year?
Here is how Novavax (NVAX) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Novavax: The Beaten-Down COVID-19 Darling
Novavax is significantly undervalued post-COVID, with a current enterprise value around $716 million and a promising pipeline led by Matrix-M. NVAX's Matrix-M adjuvant is a core value driver, validated by major partnerships with Sanofi and Pfizer, offering substantial milestone and royalty upside. Revenue is now primarily driven by licensing and royalties, with product sales from Nuvaxovid declining sharply; partnership dependence is a key risk.
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know
In the most recent trading session, Novavax (NVAX) closed at $7.37, indicating a -1.6% shift from the previous trading day.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note
Novavax (NVAX) reached $7.88 at the closing of the latest trading day, reflecting a -4.02% change compared to its last close.
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Novavax (NVAX) closed at $8.42, marking a -5.5% move from the previous day.
